Systemic Drug Delivery Strategies
Volume 2 of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy
- 1st Edition - August 21, 2021
- Imprint: Academic Press
- Editors: Mansoor M. Amiji, Lara Scheherazade Milane
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 8 5 7 8 1 - 9
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 0 9 2 5 - 9
Systemic Drug Delivery Strategies: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Volume 2 examines the challenges of delivering immuno-on… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteSystemic Drug Delivery Strategies: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Volume 2 examines the challenges of delivering immuno-oncology therapies, focusing specifically on the multiple technologies of affective drug delivery strategies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. This volume of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy discusses methods of targeting tumors, CRISPR technology, and vaccine delivery among many other delivery strategies.
Systemic Drug Delivery Strategies: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Volume 2
creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side.- Comprehensive treaty covering all aspects of immuno-oncology (IO)
- Novel strategies for delivery of IO therapeutics and vaccines
- Forecasting on the future of nanotechnology and drug delivery for IO
Scientists and clinicians working in research and development of IO therapeutics and vaccines. Graduate students and postdoctoral associate working in this field
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- Preface
- Acknowledgments
- Chapter One: Delivery strategies for immune checkpoint blockade
- Abstract
- 1: Introduction
- 2: Systemic delivery of ICIs
- 3: Local delivery of ICIs
- 4: Conclusion
- Chapter Two: Delivery strategies for ex vivo and in vivo T-cell reprogramming
- Abstract
- Acknowledgments
- 1: Introduction
- 2: Engineering techniques for drug delivery to T-cells
- 3: Therapeutic applications of delivery strategies for T-cell reprogramming in cancer
- 4: Conclusions and future directions
- Chapter Three: Targeting natural killer cells in cancer immunotherapy
- Abstract
- 1: Introduction
- 2: Exploiting NK cell immunobiology for localized therapy
- 3: Manufacturing of NK cell therapies
- 4: Challenges to NK cell therapy and the delivery of NK cells to target tumors
- 5: Immunometabolic reprogramming of NK cells in cancer
- 6: Soluble factors modulating NK cell therapy
- 7: Enhancing the immunotherapeutic potential of NK cells: Improving delivery, specificity, and activity
- 8: Concluding remarks
- Chapter Four: Delivery strategies for reprogramming tumor-associated macrophages
- Abstract
- Acknowledgments
- 1: Introduction
- 2: Delivery strategies for small molecule inhibitors in macrophage reprogramming
- 3: Nucleic acid delivery systems
- 4: Cytokine delivery for TAM repolarization
- 5: Antibody-mediated therapy
- 6: Biomaterial based macrophage modulation
- 7: Combination therapies
- 8: Concluding remarks
- Chapter Five: Delivery strategies of RNA therapeutics for ex vivo and in vivo B-cell malignancies
- Abstract
- 1: Introduction
- 2: RNAi-conjugates for ex vivo and in vivo delivery of RNAi therapeutics to malignant B-cells
- 3: Nanocarrier-based delivery of RNAi therapeutics for the in vivo manipulation of malignant B-cells
- 4: Future outlook
- Chapter Six: Targeting tumor-associated neutrophils in immunotherapy
- Abstract
- Acknowledgment
- 1: Reducing the number of tumor-associated neutrophils
- 2: Blocking immunosuppressive activity of tumor-associated neutrophils
- 3: Summary and perspective
- Chapter Seven: Targeting cancer-associated fibroblasts in immunotherapy
- Abstract
- Acknowledgments
- 1: Introduction
- 2: CAF and their role in the TME
- 3: CAF as central regulators of immune cells in the TME
- 4: CAF-targeting delivery systems
- 5: CAF targeting in immunotherapy
- 6: Clinical trials of CAF-targeted immunotherapeutics
- 7: Challenges and perspectives
- Chapter Eight: Oncolytic viral particle delivery
- Abstract
- 1: Background to oncolytic virus delivery
- 2: Nanoparticles
- 3: Pharmacokinetics of nanoparticles in oncology
- 4: Strategies to enhance delivery
- 5: Conclusions
- Chapter Nine: Extracellular vesicles in tumor immunotherapy
- Abstract
- Acknowledgments
- 1: Introduction
- 2: Biogenesis and biological functions of exosomes
- 3: Exosome immunotherapy applications
- 4: Clinical development
- 5: Future opportunities
- 6: Concluding remarks
- Chapter Ten: Nonviral gene editing in cancer immunotherapy
- Abstract
- 1: Genome editing and intracellular delivery of CRISPR/Cas9
- 2: Inorganic nanoparticles
- 3: Polymers
- 4: Lipids and lipid–polymer hybrid materials
- 5: Challenges and opportunities
- Chapter Eleven: Nucleic acid-based immune checkpoint blockade: Progress and potential
- Abstract
- 1: Introduction
- 2: Nucleic acid constructs and delivery
- 3: Immunotherapeutic targets for nucleic acid checkpoint treatment
- 4: Conclusions
- Chapter Twelve: Local and systemic delivery strategies for glioma immunotherapy
- Abstract
- 1: Introduction
- 2: Glioma microenvironment and immune responses
- 3: Immunotherapeutic approaches for glioma
- 4: Delivery challenges and a need for novel solutions
- 5: Novel delivery solutions for glioma immunotherapy
- 6: Challenges in clinical translation and future prospects
- 7: Conclusions
- Chapter Thirteen: Delivery strategies for STING agonists
- Abstract
- Acknowledgments
- 1: The fundamentals of STING biology
- 2: STING activation in cancer immunotherapy and vaccine adjuvant
- Chapter Fourteen: Delivery strategies for cancer vaccines and immunoadjuvants
- Abstract
- Acknowledgments
- 1: Introduction
- 2: Overview of immune responses important for cancer vaccines
- 3: Cancer antigens target vaccines
- 4: Common preclinical cancer models
- 5: Adjuvants are needed to boost an antigen's immune response
- 6: Formulation of cancer vaccine adjuvants and antigens
- 7: Conclusions and future directions
- Chapter Fifteen: Targeted delivery and reprogramming of myeloid-derived suppressor cells (MDSCs) in cancer
- Abstract
- 1: Phenotypes of MDSCs
- 2: Therapeutic strategies targeting each step of MDSC accumulation and the activities in cancer
- 3: Targeting expansion and trafficking of MDSCs
- 4: Potential target of MDSC-mediated immunosuppressive activities
- 5: Other functions of MDSCs and possible treatment strategies in cancer
- 6: Differentiate MDSCs into mature, nonsuppressive cells
- 7: Maximizing other therapies by targeting MDSCs
- 8: Summary
- Chapter Sixteen: Delivery of radioimmunotherapy for solid tumors
- Abstract
- Funding
- 1: Introduction
- 2: Challenges in delivery of RIT in solid tumors
- 3: Approaches to enhance the delivery of RIT in solid tumors
- 4: Conclusions and future perspective
- Chapter Seventeen: Targeted photodynamic immunotherapy
- Abstract
- Acknowledgments
- 1: Introduction
- 2: Photodynamic immunotherapy
- 3: Limitations and future perspectives
- 4: Conclusions
- Chapter Eighteen: Local immunotherapy of cancer and metastasis
- Abstract
- 1: Introduction
- 2: Types of cancer immunotherapy
- 3: Chemotherapy in cancer immunotherapy
- 4: Delivery of cancer immunotherapy agents
- 5: Evaluation of local immunotherapy in preclinical studies
- 6: Conclusion
- Chapter Nineteen: Delivery strategies to overcome tumor immunotherapy resistance
- Abstract
- 1: Cancer immunotherapy
- 2: Tumor immunotherapy resistance
- 3: Delivery strategies to overcome tumor immunotherapy resistance
- 4: Discussion
- Index
- Edition: 1
- Published: August 21, 2021
- No. of pages (Paperback): 588
- No. of pages (eBook): 588
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780323857819
- eBook ISBN: 9780323909259
MA
Mansoor M. Amiji
Mansoor M. Amiji is the Distinguished Professor and Chairman of the Department of Pharmaceutical Sciences at the Bouvé College of Health Sciences at Northeastern University. Dr. Amiji has edited a number of books and is a frequently published author. His research focuses on the synthesis of novel polymeric materials for medical and pharmaceutical applications, drug delivery systems and nanomedical technologies, and his contributions in research advising, grant reviews for various organizations and editorial work for journals are invaluable.
Affiliations and expertise
Distinguished Professor and Chairman, Department of Pharmaceutical Sciences, School of Pharmacy, Bouve College of Health Sciences, Northeastern University, Boston, Massachusetts, USALM
Lara Scheherazade Milane
Dr. Lara Milane is Assistant Teaching Professor in Biotechnology at the Bouvé College of Health Sciences at Northeastern University. She is interested in Mitochondrial Medicine. She is working on developing nanomedicines for a range of diseases (cancer, neurodegenerative disease, aging) that manipulate mitochondria for therapeutic outcomes. Dr. Milane was trained as a National Cancer Institute/ National Science Foundation Nanomedicine Fellow at Northeastern University, Boston, MA. Dr. Milane is an intuitive cancer biologist with research interests in developing translational nanomedicines that exploit the hallmarks of cancer.
Affiliations and expertise
Assistant Teaching Professor in Biotechnology, Bouve College of Health Sciences, Northeastern University, USARead Systemic Drug Delivery Strategies on ScienceDirect